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Abstract: Single wall carbon nanotube (SWCNT) constructs were covalently appended with 
radiometal-ion  chelates  (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic  acid  [DOTA] 
or  desferrioxamine  B  [DFO])  and  the  tumor  neovascular-targeting  antibody  E4G10.  The 
E4G10 antibody specifically targeted the monomeric vascular endothelial-cadherin (VE-cad) 
epitope expressed in the tumor angiogenic vessels. The construct specific activity and blood 
compartment clearance kinetics were significantly improved relative to corresponding antibody-
alone constructs. We performed targeted radioimmunotherapy with a SWCNT-([225Ac]DOTA)
(E4G10) construct directed at the tumor vasculature in a murine xenograft model of human 
colon adenocarcinoma (LS174T). The specific construct reduced tumor volume and improved 
median survival relative to controls. We also performed positron emission tomographic (PET) 
radioimmunoimaging of the tumor vessels with a SWCNT-([89Zr]DFO)(E4G10) construct in 
the same murine LS174T xenograft model and compared the results to appropriate controls. 
Dynamic and longitudinal PET imaging of LS174T tumor-bearing mice demonstrated rapid blood 
clearance (,1 hour) and specific tumor accumulation of the specific construct. Incorporation 
of the SWCNT scaffold into the construct design permitted us to amplify the specific activity to 
improve the signal-to-noise ratio without detrimentally impacting the immunoreactivity of the 
targeting antibody moiety. Furthermore, we were able to exploit the SWCNT pharmacokinetic 
(PK) profile to favorably alter the blood clearance and provide an advantage for rapid imaging. 
Near-infrared  three-dimensional  fluorescent-mediated  tomography  was  used  to  image  the 
LS174T tumor model, collect antibody-alone PK data, and calculate the number of copies 
of VE-cad epitope per cell. All of these studies were performed as a single administration of 
construct and were found to be safe and well tolerated by the murine model. These data have 
implications that support further imaging and radiotherapy studies using a SWCNT-based 
platform and focusing on the tumor vessels as the target.
Keywords: actinium-225 (225Ac), zirconium-89 (89Zr), angiogenesis, vascular   endothelial- 
cadherin, radioimmunotherapy (RIT), radioimmunoPET
Introduction
Advances in cancer diagnosis and therapy require improvements in the agents used to 
image and treat disease. Valuable modifications include those that enable these agents 
to specifically target disease, increase signal-to-noise, rapidly clear from the blood, 
and incorporate multiple imaging and therapeutic modalities. Carbon nanomaterials 
are being investigated as delivery platforms for diagnostic and therapeutic cargoes to 
target disease.1,2 Pharmacokinetic (PK) studies of soluble, covalently-functionalized, 
radiolabeled carbon nanotubes (CNTs) have demonstrated rapid blood compartment International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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clearance, high specific activity (SA), multimodal imaging 
capability, renal elimination, and tumor-specific accumulation 
in vivo.3–6 Implementation of an imaging and therapeutic 
drug construct that is designed to target, report location, and 
irradiate the tumor vessels is a key strategic modification that 
will take advantage of the single wall CNT (SWCNT)-based 
  construct’s chemical, radiochemical, and PK properties.
Many cancers are characterized by an extensive angio-
genic, aberrant vascular network that supports the tumor 
proliferation and survival. The endothelial vessels in tumors 
often do not exhibit the same organizational hierarchy of 
arterioles, capillaries, and venules present in normal   tissue. 
Instead, tumor vessels are tortuous and have abnormal 
component and structural composition. Endothelial cells 
in these tumors are inefficiently and irregularly joined with 
holes, gaps, and defects; pericytes are absent or loosely 
associated with vessels; and basement membranes are 
inefficiently applied relative to typical normal tissues. The 
pore diameters of tumor typically range from 40 to 80 nm. 
Large interendothelial junctions in cancerous tissue may be 
as large as 500 nm, whereas in healthy tissue, these junc-
tions are ∼8 nm.7 Angiogenic endothelial cells express the 
monomeric vascular endothelial-cadherin (VE-cad) epitope 
on the cell surface that upon dimerizing with another mono-
meric copy of VE-cad on an adjoining cell surface leads to the 
formation of tight adherens junctions between the cells.8–12 
The antibody E4G10 binds only to the monomeric VE-cad 
and not to the homodimeric form (the binding region is 
masked in the homodimers that form the tight cell–cell con-
tacts), thus conferring the specificity for targeting angiogenic 
and poorly joined endothelial cells in vivo while not binding 
to normal endothelium or the LS174T tumor.
The alpha particle-emitting radionuclide actinium-225 
(225Ac; t1/2 = 10 days) attached to monoclonal antibodies 
(immunoglobulin [Ig]G) has been used as the therapeutic 
effector moiety in a number of preclinical studies13–18 and 
is currently in clinical use.19–21 Alpha particles are charged 
helium nuclei that travel ∼50–80 µm, which is similar to the 
dimensions of vessels within a tumor. The alpha particle track 
lengths appropriately match the vessel dimensions, and a 
single traversal through a cell of a high linear energy transfer 
(LET) alpha particle can be acutely cytotoxic.22,23 Typical 
tumor vasculature is ,100 µm in diameter, and smaller ves-
sels are ,10 µm in diameter. In addition, individual alpha 
particles are able to kill a target cell due to their deposition 
of 5–8 MeV in a short ionizing track that is several cell diam-
eters in length.23 This highly concentrated field of ionizing 
radiation may also irradiate the cancer stem cell population 
that can be found in the adjacent perivascular niche of some 
tumors.24–26 Alpha particles are very potent cytotoxic agents in 
proximity to the targeted tissue but will largely spare normal 
tissue; it is this characteristic that offers clear advantages 
to other known forms of radiation as a means of selective 
cell killing. We have previously demonstrated the utility of 
225Ac-radiolabeled E4G10 constructs to target and irradiate 
tumor vascular endothelium in animal models, improve 
survival, control tumor growth, and normalize the vessels27 
and also the ability of the construct to target and eradicate 
bone marrow-derived endothelial progenitors.28
Zirconium-89 (89Zr) is now being developed as one of the 
most promising new immuno-positron emission tomography 
(PET) agents for in vivo imaging of cancer.29–34 PET is based 
on coincidence detection of a positron-emitting radionuclide 
from 2 coincident 511 keV annihilation photons emitted 
simultaneously in opposite directions.35 The clinical use 
of PET has emerged as an important diagnostic imaging 
modality for humans because it provides extremely sensitive, 
quantitative, and functional information that is different from 
the information obtainable with other largely anatomical 
imaging modalities.35 The physical decay properties of 89Zr 
(t1/2 = 78.41 hours; electron capture = 76.6%; β+ = 22.3%) 
are well suited for use in the design of imaging agents with 
extended PK profiles. Recently, reported improvements in 
the separation chemistry of 89Zr from the yttrium-89 (89Y) 
target material have yielded a facile process for production 
of clinical-grade, high SA  89Zr using a small cyclotron.30 
This process should lead to more widespread use of this 
radionuclide.
The rationale for using SWCNTs as the scaffold in 
our construct design is the following: SWCNTs are made 
almost entirely of carbon, are nonimmunogenic, and can 
be chemically modified.36–38 The commercially available 
SWCNTs have a diameter of 1–2 nm and lengths of 
100–1,000 nm. Thus, SWCNTs have extremely high aspect 
ratios with estimated surface areas of 1,600 m2/g. On the 
atomic level, SWCNTs have highly regular structures with 
defined periodicity. For every 100 nm of length, a SWCNT 
can have up to 12,200 carbon atoms and weighs 150,000 Da, 
providing numerous sites (typically 1 in 95 carbons was modi-
fied) for chemical modifications and anchoring chemical, 
biological, and radionuclide moieties.3–6 SWCNTs that have 
been chemically functionalized with sidewall amino groups 
exhibit aqueous solubility and reactivity towards a variety of 
reagents under mild bioconjugation conditions.3–6,36–39 The 
SWCNTs appended with amines and the metal-ion chelate 
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(DOTA) were water soluble (∼20 g/L) and studied in vivo 
in animal models.3–6 Our data showed that these SWCNTs 
rapidly (t1/2 , 1 hour) cleared the blood and prototype 
SWCNT constructs (diameter = ∼1 nm; length = ∼300 nm; 
moleculer weight = ∼500 kD) were predominantly eliminated 
intact within minutes via glomerular filtration through the 
renal pathway. Renal excretion was found to be facilitated 
by the high aspect ratio of SWCNT, which confers lower 
rotational diffusivity; thus, the CNT tends to orient with the 
blood flow allowing easy access to the glomerular pores.6 
Other recent work described the enzymatic degradation 
of functionalized SWCNT in vitro and in vivo, offering 
the potential for metabolic decomposition of CNT drug 
constructs.40–43 Further, toxicity studies have confirmed 
the safe in vivo use of functionalized SWCNT.44–47 Taken 
together, these data on renal elimination, enzymatic degrada-
tion, and lack of toxicity support continued investigation of 
SWCNT as a platform in drug development.
We hypothesize that CNT constructs can be covalently 
multifunctionalized with copies of targeting moieties and 
different reporting and therapeutic radionuclides and, thereby, 
increase signal-to-noise ratio and be used to image tumor 
vessels and improve the therapeutic index. The underlying 
rationale for this approach is that we are specifically target-
ing the aberrant and angiogenic tumor vessels and deliver-
ing a dose of short range (1–4 cell diameters), high energy 
(several million electron volts) cytotoxic alpha particles to 
the targeted area. In addition, we will report the location of 
the drug construct. This approach is novel because it will 
examine the attributes of targeted radioimmunotherapy (RIT) 
with alpha particle generators, sensitive and quantitative PET 
imaging, and the specificity of the targeting E4G10 antibody 
in combination with the unique nanomaterial properties 
of SWCNT.
Material and methods
Ls174T xenograft model in nude mice
Athymic nude mice (NCr nu/nu, male), 4–12 weeks of age, 
were obtained from Taconic, Germantown, NY, USA. For all 
in vivo experiments, housing and care were in accordance 
with the Animal Welfare Act and the Guide for the Care 
and Use of Laboratory Animals. The animal use protocols 
were approved by the Institutional Animal Care and Use 
Committee, Memorial Sloan-Kettering Cancer Center. 
Human LS174T cells (human colon adenocarcinoma) 
were expanded in Dulbecco–Vogt Modified Eagle’s media 
supplemented with glucose, nonessential amino acids, 
l-glutamine, and 10% fetal bovine serum in an atmosphere 
of 5% CO2 and air at 37°C. Cells were harvested and mixed 
with MatrigelTM (BD Biosciences, Palo Alto, CA, USA), and 
0.1 mL of ∼2–3E6 cells were injected subcutaneously into 
the right hind flank of each animal.
construct design and syntheses
SWCNTs (Nanolab, Newton, MA, USA) were covalently 
amine functionalized as described previously.3–6,36–39 The 
SWCNT-NH2 product was purified from carbonaceous 
impurities using a C18 Sep-Pak® (Waters, Milford,   MA, USA) 
and analyzed by high-performance   liquid   chromatography 
(HPLC), Raman spectroscopy, and   transmission electron 
microscopy (TEM).3–6 Amine   loading was determined using 
the Sarin assay, whereas TEM and Raman spectroscopy were 
performed as described previously.3–6 Table 1 provides a list 
of the key drug   constructs, the corresponding nomenclature, 
studies   performed, and the SA values for the therapeutic and 
  imaging studies from this work.
The RIT drug Construct I (Figure 1A) was designed 
to specifically target the tumor vessels and deliver the 
potent alpha particle-emitting  225Ac radionuclide gen-
erator.13 The key SWCNT precursor to Construct I 
was assembled by first converting a fraction of the pri-
mary amines on the SWCNT-NH2 construct to reactive 
hydrazinopyridine (HNH) moieties. Briefly, 0.5 g of SWCNT-
NH2 was dissolved in 1 mL of 100 mM sodium phosphate 
(NaH2PO4 and Na3PO4; Sigma-Aldrich, St Louis, MO, 
USA)/150 mM sodium chloride (NaCl; Sigma-Aldrich), pH 
7.8 buffer. Immediately before use, 5.5 mg of succinimidyl 
4-hydrazinonicotinate acetone hydrazone (SANH; Solulink 
Inc, San Diego, CA, USA) was dissolved in 0.2 mL of dry 
N,N-dimethylformamide (DMF; Sigma-Aldrich). An aliquot 
Table 1 Construct nomenclature, designation, study use, and specific activity
Construct nomenclature Designation Study High SA (Ci/g) Low SA (Ci/g)
sWcNT-([225Ac]DOTA)(e4g10) construct I RIT 23 0.05
sWcNT-([225Ac]DOTA)(anti-KLh) control construct I RIT 23 NA
sWcNT-([89Zr]DFO)(e4g10) construct II RII 16 NA
sWcNT-([89Zr]DFO)(anti-KLh) control construct II RII 16 NA
Abbreviations: SA, specific activity; SWCNT, single wall carbon nanotube;  225Ac, actinium-225; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; RIT, 
radioimmunotherapy; anti-KLh, anti-keyhole limpet hemocyanin; 89Zr, zirconium-89 DFO, desferrioxamine B; RII, radioimmunoimaging.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 graphical representations of the key moieties that were appended to the water-soluble sWcNT-Nh2 by covalent-functionalization with radionuclides, DOTA, 
DFO, and antibodies (Note, not drawn to scale). A) Radioimmunotherapeutic drug construct I (sWcNT-([225Ac]DOTA)(e4g10)). B) Radioimmunoimaging drug construct II 
sWcNT-([89Zr]DFO)(e4g10).
Abbreviations: sWcNT, single wall carbon nanotube; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DFO, desferrioxamine B;  225Ac, actinium-225; 
89Zr, zirconium-89.
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of SANH/DMF solution was added to the SWCNT-NH2 to 
achieve a 0.25-fold mole ratio of SANH to primary amine. 
The reaction proceeded at ambient temperature for 2–3 hours 
at pH 7.6. The product, SWCNT-(HNH)(NH2), was purified 
using size exclusion chromatography (SEC) with a 10 DG 
gel permeation column (Bio-Rad Laboratories, Hercules, CA, 
USA) as the stationary phase and metal-free water (MFW; 
Purelab Plus System, US Filter Corp, Lowell, MA, USA) 
as the mobile phase. The product was lyophilized to yield a 
solid that was found to be the desired SWCNT-(HNH)(NH2) 
construct.
The second step entailed covalently appending multiple 
copies of 2-(p-isothiocyanatobenzyl)-DOTA (DOTA-NCS; 
Macrocyclics, Inc, Dallas, TX, USA) to the remaining amines 
on the water-soluble SWCNT-(HNH)(NH2) construct to yield 
a SWCNT-(DOTA)(HNH) construct in metal-free conditions 
at pH 9.5 (adjusted with 1 M metal-free carbonate solution) 
for 40 minutes at room temperature at a stoichiometry of 
10:1 (DOTA-NCS to amine).3–6 The product was purified 
using a 10 DG gel permeation column with MFW as the 
mobile phase. The 10 DG column was rendered metal free 
by washing with 50 mL of 25 mM EDTA (Sigma-Aldrich) 
followed by rinsing with 250 mL of MFW. The product was 
lyophilized to yield a solid that was found to be the desired 
SWCNT-(DOTA)(HNH) construct.
SWCNT-(DOTA)(HNH) + 225Ac →
  SWCNT-([225Ac]DOTA)(HNH)  (1)
225Ac radionuclide was obtained from the US Department 
of Energy’s Oak Ridge National Laboratory (Oak Ridge, TN, 
USA). Methods for radiolabeling and purification of a MFW 
solution of SWCNT-(DOTA)(HNH) with 225Ac at pH 5 are 
similar to those described previously.48 Briefly, 0.18 mg of 
SWCNT-(DOTA)(HNH) in 0.02 mL of MFW was reacted 
with 0.005 mL of 225Ac in 50 mM optima grade hydrochloric 
acid (HCl; Fisher Scientific, Pittsburgh, PA, USA) along with 
0.02 mL of 150 g/L l-ascorbic acid (Sigma-Aldrich) and 
0.2 mL of 3 M tetramethylammonium acetate (Fisher Scien-
tific) buffer, pH 5.5, at 60°C for 60 minutes (reaction 1). Puri-
fication was accomplished using SEC with a P6 gel stationary 
phase and a phosphate buffer saline (PBS) mobile phase. 
Chemicals used in the radiolabeling and purification steps 
were of American Chemical Society reagent-grade or higher 
purity. The labeling solutions were prepared and subsequently 
rendered metal free with Chelex® 100 resin, 200–400 mesh, 
sodium form (Bio-Rad Laboratories), and sterile filtered 
through a 0.22 or 0.45 µm filter device.   Solutions of 50 mM 
diethylenetriaminepentaacetic acid (DTPA; Sigma-Aldrich) 
were sterile filtered and used to quench the labeling reac-
tion prior to SEC. Human serum albumin (HSA; Swiss Red 
Cross, Bern, Switzerland) and 0.9% NaCl (Abbott Labora-
tories, North Chicago, IL, USA) were used as received.225Ac 
activity was measured with a Squibb CRC-17 Radioisotope 
Calibrator (or equivalent model; E.R. Squibb and Sons, Inc, 
Princeton, NJ, USA) set at 775 and multiplying the displayed 
activity value by 5 to report the activity.
Instant thin layer chromatography using silica gel 
impregnated paper (ITLC-SG; Gelman Science Inc, Ann 
Arbor, MI, USA) was used to determine the labeling 
efficiency of the reaction mixture and the purity of the 
product. Briefly, a 0.001 mL aliquot was spotted onto 
the paper strips and developed using 2 different mobile 
phases.13,23,48 Mobile phase 1 was 10 mM EDTA and 2 
was 9% NaCl/10 mM sodium hydroxide (NaOH; Sigma-
Aldrich). The Rf of the radiolabeled construct was 0 and any 
free metal species and metal chelates were characterized by 
Rf of 1.0 in mobile phase 1. In mobile phase 2, the radiola-
beled construct and free metal  species were characterized 
by Rf of 0 and the metal chelates by Rf of 1.0. The strips 
were counted intact using a System 400 Imaging Scanner 
(Bioscan Inc, Washington, USA).
  E4G10 + SFB → E4G10-FB  (2)
The next key step (reaction 2) was the conversion of the 
VE-cad-specific IgG (E4G10; Imclone Systems, New York, 
NY, USA) or the isotype control anti-keyhole limpet hemo-
cyanin (anti-KLH) IgG (R&D Systems, Minneapolis, MN, 
USA) to the reactive arylaldehyde modified–IgG precursors. 
Briefly, immediately before use, 15 mg of succinimidyl 
4-formylbenzoate (SFB; Solulink Inc) was dissolved in 
0.5 mL DMF. An aliquot of this modification solution was 
added to 2.5 mg of E4G10 protein (5 g/L; or the isotype 
control IgG) to achieve a 10–20 fold molar excess of the 
reagent. The reaction mixture was incubated at 37°C for 
2–3 hours. Purification of the arylaldehyde modified–IgG was 
performed by SEC as described above. The modified proteins 
were stored at 4°C. The stoichiometry of substitution (moles 
of formylbenzoate [FB] per mole IgG) was determined first 
by assaying the protein concentration using the bicinchoninic 
acid (BCA) protein assay (Pierce, Rockford, IL, USA) and the 
moles of FB per mole IgG using the 2-HNH-dihydrochloride 
(2-HP; Solulink) quantification assay. Briefly, the addition of 
a molar excess 2-HP to the FB moiety on E4G10 at pH 4.7 
permitted the measurement of the molar substitution ratio by International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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electronic absorption spectroscopy using the arylhydrazone 
chromophore (maximum absorption [Absmax] = 350 nm, 
ε = 18,000 M−1 cm−1).
SWCNT-([225Ac]DOTA)(HNH) + E4G10-FB →
      SWCNT-([225Ac]DOTA)(E4G10)  (3)
The E4G10-FB antibodies were covalently attached to the 
SWCNT-([225Ac]DOTA)(HNH) by the reaction of 0.05 mg of 
SWCNT-([225Ac]DOTA)(HNH) with 0.17 mg of E4G10-FB 
in 1.2 mL of 100 mM sodium phosphate/150 mM NaCl, 
pH 5.2 buffer (reaction 3). A similar chemical scheme was 
used to append several of the anti-KLH-FB moieties to the 
SWCNT-([225Ac]DOTA)(HNH) precursor to yield the control 
Construct I. The reaction mixture was incubated at 37°C for 
several hours, and the high and low SA SWCNT-([225Ac]
DOTA)(E4G10) (Construct I) and isotype control Construct 
I products were stored at 4°C. The products were formulated 
into 1% HSA for injection.
The radioimmunoimaging (RII) drug Construct II 
(Figure 1B) was designed to specifically target the tumor 
vessels and deliver the positron-emitting 89Zr radionuclide 
for PET imaging. The key precursor to Construct II was 
assembled first by appending multiple copies of the reactive 
arylaldehyde, SFB. Briefly, the SFB was dissolved in 0.1 mL 
DMF and a volume of this modification solution was added 
to 0.5 mg of SWCNT-NH2 (3 g/L) to achieve a ratio of 5 SFB 
per 100 amines. The reaction mixture was incubated at 37°C 
for 2–3 hours. Purification of the arylaldehyde modified–
SWCNT was performed by SEC as described above. The 
stoichiometry of substitution was determined (moles of FB 
per gram SWCNT) using the 2-HP quantification assay as 
described previously. Then, the remaining amines on the 
SWCNT-(FB)(NH2) construct were covalently modified by 
appending the desferrioxamine B (DFO) chelate. The details 
of preparation of the reactive DFO intermediate reagent are 
described below.
The synthesis of N-succinylDFO (N-succDFO) was 
  performed by the reaction of DFO mesylate (0.508 g, 
0.77 mmol; Calbiochem, Spring Valley, CA, USA) dissolved 
in 7.5 mL of pyridine (Sigma-Aldrich) with excess (1.704 g, 
0.017 mol) succinic anhydride (Sigma-Aldrich) at room 
temperature for 24 hours. The resulting white suspension 
was then poured into an aqueous NaOH solution (120 mL, 
0.015 M) and stirred at room temperature for 16 hours. The 
colorless solution was adjusted to pH 2 by the addition of 12 
M HCl and cooled with stirring at 4°C for 2 hours. The white 
precipitate was collected by filtration, washed with copious 
amounts of 0.01 M HCl and then water, and dried in a vacuum 
to give the N-succDFO as a white microcrystalline solid 
(0.306 g, 4.75 × 10−4 mol).
The preparation of ferric DFO-2,3,5,6-tetrafluorophenol 
(Fe[DFO-TFP]) was performed by reacting the activated 
ester N-succDFO (9.0 mg, 0.014 mmol), suspended 
in 3 mL of 0.9% sterile saline and the pH adjusted to 
6.5, with 0.05–0.075 mL of 0.1 M sodium carbonate 
(Na2CO3; Sigma-Aldrich). A solution of ferric trichloride 
hexahydrate (FeCl3 6H2O [4 mg, 0.015 mmol, 0.3 mL of 0.1 
M HCl]; Sigma-Aldrich) – was added to this N-succDFO 
solution. Upon addition of the FeCl3, the reaction mixture 
changed from colorless to deep orange due to the intense 
electronic absorption band of Fe(DFO) with a peak at 
430 nm (ε430 = 2,216 ± 49 M−1 cm−1). After stirring the 
reaction mixture at room temperature for 1 hour, a 1.2 M 
solution of TFP (0.3 mL, 0.036 mmol; Sigma-Aldrich) 
in Chelex-purified acetonitrile (MeCN; Sigma-Aldrich) 
was added to the reaction followed by the addition of 
solid N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0120 mg, 0.63 mmol; Sigma Aldrich). 
The reaction mixture (pH 6.5) was then stirred at room 
temperature for 1 hour before purifying the Fe(DFO-TFP) 
product using a C18 Light Sep-Pak cartridge (Waters). The 
reaction mixture was loaded onto a preactivated (6 mL 
MeCN and 10 mL H2O) C18 cartridge, washed with copi-
ous amounts of water (.40 mL), and eluted with 1.5 mL 
MeCN. The final Fe(DFO-TFP) solution had a concentra-
tion of ∼9.8 mM. The Fe(DFO-TFP) solution was stored 
at 4ºC.
The Fe(DFO-TFP) reagent was then reacted with the 
remaining amines on the SWCNT-(FB)(NH2) construct 
to introduce the DFO chelate onto the SWCNT precursor. 
The Fe was removed by exposing the metallated precursor 
to a 10-fold excess of EDTA (0.0674 M, 0.0137 mmol, 
0.03 mL) with respect to Fe(N-succDFO-TFP). The reaction 
was incubated in a water bath at 38°C for 1 hour. The 
SWCNT-(DFO)(FB) was purified by SEC chromatography 
to render it Fe free and was ready to be radiolabeled 
(reaction 4).
  SWCNT-(DFO)(FB) + 89Zr → 
  SWCNT-([89Zr]DFO)(FB)  (4)
89Zr was produced via the  89Y(p,n)89Zr transmutation 
reaction on an EBCO TR19/9 variable-beam-energy 
cyclotron (Ebco Industries Inc, Richmond, BC, Canada) 
in accordance with previously reported methods.30 The International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
789
Targeting angiogenic tumor vasculature with carbon nanotubes
89Zr-oxalate was isolated in high radionuclidic and 
radiochemical purity (RCP) .99.9%, with an effective 
SA of 195–497 TBq/g, (5,280–13,430 Ci/g).30 Methods 
for radiolabeling and purification of a 10 g/L solution 
of SWCNT-(DFO)(FB) in MFW with  89Zr at pH 5 are 
similar to those described previously.30 Briefly, 0.1 mg of 
SWCNT-(DFO)(FB) in 0.02 mL of MFW was reacted with 
122.5 MBq (3.31 mCi) of 89Zr in 0.005 mL of 1 M oxalic 
acid (Sigma-Aldrich), pH 6.5. The pH was adjusted to 8.1 
with the addition of 0.17 mL of 1.0 M Na2CO3. The reac-
tion was heated to 60°C for 60 minutes. Purification was 
accomplished using SEC with a P6 gel stationary phase 
and a PBS mobile phase.89 Zr activity was measured with 
a Squibb CRC-17 Radioisotope Calibrator (or equivalent 
model) set at 465. ITLC-SG was used to determine the 
labeling efficiency of the reaction mixture and the purity of 
the product. The strips were counted intact using a System 
400 Imaging Scanner (or equivalent).
  E4G10 + SANH → E4G10-HNH  (5)
The next key step was the conversion of the E4G10 
or the isotype control anti-KLH IgGs to the reactive 
arylhydrazine modified–IgG precursors (reaction 5). 
Briefly, 1 mg of IgG was dissolved in 0.2 mL of 100 mM 
sodium phosphate/150 mM NaCl, pH 7.6 buffer. Immedi-
ately before use, 2–4 mg of SANH was dissolve in 0.1 mL 
of dry DMF. A volume of SANH/DMF solution was added 
to the IgG to achieve a 10–20 fold molar excess of the 
SANH to antibody. The reaction proceeded at ambient 
temperature for 2–3 hours at pH 7.6. The product, IgG-
HNH, was purified using SEC with a 10 DG gel column 
as the stationary phase and 100 mM 2-(N-morpholino) 
ethanesulfonic acid (MES; Sigma-Aldrich)/150 mM 
NaCl conjugation buffer at pH 5.4 as the mobile phase. 
The amount of HNH substituent per IgG was determined 
first by assaying the protein concentration using the BCA 
protein assay and the moles of arylhydrazine (HNH) per 
mole IgG using the 4-nitrobenzaldehyde (4-NBA; Solulink) 
quantification assay. Addition of a molar excess 4-NBA to 
the HNH moiety on IgG at pH 4.7 permitted the measure-
ment of the molar substitution ratio of the   chromophore 
(Absmax = 390 nm, ε = 24,000 M−1 cm−1).
SWCNT-([89Zr]DFO)(FB) + E4G10-HNH → 
      SWCNT-([89Zr]DFO)(E4G10)  (6)
The E4G10-HNH antibodies (or anti-KLH-HNH) were 
covalently attached to the SWCNT-([89Zr]DFO)(FB) by the 
reaction of 0.1 mg of SWCNT-([89Zr]DFO)(FB) with 0.3 mg 
of E4G10-HNH in 0.25 mL of 100 mM MES/150 mM NaCl 
conjugation buffer at pH 4.7 (reaction 6). The reaction mixture 
was incubated at 37°C for several hours. The SWCNT-([89Zr]
DFO)(E4G10) (Construct II) and isotype control Construct 
II products were stored at 4°C and were formulated into 1% 
HSA for injection.
Amplification of construct specific 
activity
A fixed mass of SWCNT-(DOTA)(HNH) precursor was 
radiolabeled with varying amounts of  225Ac activity to 
determine the reaction yields and specific activities. In 
each of 5 radiolabeling reactions, the volume, pH, time, 
temperature, and reagent concentrations were held con-
stant (see specific conditions described above), while only 
the amount of radionuclide was varied. Briefly, 0.18 mg 
of SWCNT-(DOTA)(HNH) was  225Ac-radiolabeled in 
0.4 mL, at pH 5.5, at 60°C for 60 minutes in 5 different 
reactions. In amplification reaction 1, the SWCNT-(DOTA)
(HNH) was labeled with 0.444 MBq (0.012 mCi); 2, 1.48 
MBq (0.04 mCi) was used; 3, 2.26 MBq (0.061 mCi) was 
used; 4, 21.1 MBq (0.57 mCi) was used; and 5, 193 MBq 
(5.21 mCi) was used. An aliquot of each reaction was 
assayed using ITLC-SG (see above), and then, the reaction 
was quenched with the addition of DTPA. The reaction 
mixture was then purified by SEC (see above) and the 
purified product assayed by ITLC-SG and the recovered 
activity measured.
Data for numerous preclinical radiolabeling prepara-
tions of 225Ac-E4G10 were also compiled for comparison. 
The radiolabeling data using our published methods48 
from 11-dose preparations that used 0.75 ± 0.13 mg 
(mean ± standard deviation) of E4G10 and 93.6 ± 51.1 
MBq (2.53 ± 1.38 mCi) of  225Ac per dose were used as 
comparison to the results from the SWCNT-(DOTA)(HNH) 
labeling study.
As a further demonstration of the consistency of our 
published 2-step IgG radiolabeling methodology, lintuzumab 
(Protein Design Labs, Inc, Mountain View, CA, USA), a 
monoclonal IgG that targets CD33 on leukemia cells, was 
routinely radiolabeled with  225Ac for a Phase I clinical 
trial to produce  225Ac-lintuzumab. The radiolabeling data 
from 17 clinical dose preparations that used 1.4 ± 0.5 mg 
(mean ± standard deviation) of lintuzumab and 91 ± 55.1 
MBq (2.46 ± 1.49 mCi) of  225Ac were also included as 
comparison to the results from the SWCNT-(DOTA)(HNH) 
labeling study.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Three-dimensional fluorescent-
mediated tomography imaging study to 
assess the PK of e4g10 and determine 
the number of Ve-cad monomer 
epitopes per cell in vivo
Three-dimensional fluorescent-mediated tomography (FMT) 
experiments were performed by using the FMT-2500 (VisEn 
Medical, Boston, MA, USA) to determine the PK profile of 
the of E4G10 (and anti-KLH isotype control) IgGs and the 
number of binding sites per newly formed vascular endothe-
lial cell in the LS174T xenograft model.
The E4G10 and anti-KLH antibodies were reacted 
with the succinimidyl ester of Alexa Fluor® 680 carboxylic 
acid (AF680; Invitrogen, Carlsbad, CA, USA) per the 
manufacturer’s instructions to prepare 2 antibody constructs 
for an in vivo near-infrared (NIR) FMT imaging study. 
Briefly, the constructs were prepared by the reaction of a 
10–20 fold mole excess of the succinimidyl ester of the 
AF680 dye per milligram of IgG at pH 8 for 2 hours at 
ambient temperature. The dye-labeled constructs were puri-
fied by SEC chromatography as described above and charac-
terized by UV-visible spectroscopy (measured the absorbance 
at 280 and 679 nm per the manufacturer’s instructions) and 
SEC HPLC. The HPLC system used a Beckman Coulter Sys-
tem Gold Bioessential 125/168 diode array detection system 
(Beckman Coulter, Fullerton, CA, USA) equipped with an 
in-line Jasco FP-2020 fluorescence detector (Tokyo, Japan). 
The stationary phase was a Tosoh Science G3000SWXL 
column (300 mm × 7.8 mm, 5 µm; Fisher Scientific) and a 
20 mM sodium acetate (Sigma-Aldrich), 150 mM NaCl, pH 
6.4, mobile phase at 1 mL/min at ambient temperature.
Two groups of 5 nude mice with the LS174T tumor were 
randomly assembled, and each mouse received 0.03 mg of 
the construct in 0.1 mL in 1% HSA via intravenous (IV) 
retro-orbital sinus injection. NIR FMT imaging was per-
formed every 24–48 hours over a 7-day time period by using 
the specific 680 channel (excitation/emission [Ex/Em]: 
680 nm/700 nm). The volume of interest (VOI) was drawn 
over the whole tumor (as visualized by the 3-dimensional 
photographic image acquisition), and fluorescence uptake was 
quantified. Mice were maintained on a diet of low-fluorescence 
chow (AIN76A; Harlan Teklad, Wisconsin) to minimize back-
ground noise. The FMT device was calibrated for use with 
sample standards of the E4G10-AF680 and anti-KLH-AF680 
constructs in accordance with the manufacturer’s guidelines. 
The values obtained from the measurements of these standards 
of the injected dose were entered into the TrueQuant software 
(VisEn Medical) to allow for quantification.
To determine the number of VE-cad epitopes in these 
tumors, we employed the data obtained from Hilmas and 
Gillette49 that reported a morphometric analyses of tumor 
microvasculature during growth. Their data described 
changes in the tumor vascular volume, vessel diameter, 
mean vessel length, and surface area per unit volume of 
tumor tissue. Further, it was assumed that a VE cell has an 
area50 of 1E-3 mm2 (0.141 mm × 0.007 mm) and that there 
were 1E9 cells per gram of tumor. The data of Hilmas and 
Gillette49 reported that a 500 mm3 tumor had a vascular 
surface area per tumor volume of 13 mm2/mm3 and as the 
tumor volume increased (up to 1,500 mm3), the ratio of 
vascular surface area per tumor volume decreased and lev-
eled at 12 mm2/mm3.
RIT study to target and irradiate the tumor 
vasculature (survival and tumor regression)
A RIT study was performed in the LS174T xenograft tumor 
model with SWCNT-([225Ac]DOTA)(E4G10) vs appropriate 
controls. Briefly, tumor cells were xenografted 13 days before 
treatment (the mean ± standard deviation tumor volumes for 
the animals in this study were 179 ± 112 mm3 at the time RIT 
commenced). Mice were randomly separated into 4 groups 
before treatment, and all mice received a single IV dose of 
drug (or vehicle control) via the retro-orbital sinus except one 
mouse in group 1 that received a single intraperitoneal injec-
tion to investigate tumor targeting by that administration route. 
Group 1 mice (n = 6) each received a single dose of the high 
SA = 851 GBq/g SWCNT (23 Ci/g) Construct I containing 
16.1 kBq (435 nCi) 225Ac, 19 ng SWCNT, and 29 ng E4G10. 
Group 2 mice (n = 5) each received a single dose of the high 
SA = 851 GBq/g SWCNT (23 Ci/g) isotype control Construct I 
containing 15.2 kBq (410 nCi) 225Ac, 18 ng SWCNT, and 27 ng 
anti-KLH. Group 3 mice (n = 5) each received a single dose 
of the low SA = 1.9 GBq/g SWCNT (0.05 Ci/g) Construct I 
containing 0.037 kBq (1 nCi) 225Ac, 19 ng SWCNT, and 29 ng 
E4G10. Group 4 mice (n = 4) each received a single dose of 
normal saline and served as a growth control. Mice were 
observed daily and tumor volumes measured and recorded. The 
tumor volumes were assessed using calipers to measure the 
diameters and the volume was calculated as V = a × b2 × 0.52, 
where a is the longest diameter and b is the shortest diameter. 
When tumor volumes reached 1,000 mm3 or greater, mice 
were euthanized. Survival was analyzed as a function of time 
from treatment using Kaplan–Meier analysis.
RII study of tumor vasculature
A RII study was performed in the LS174T xenograft tumor 
model with SWCNT-([89Zr]DFO)(E4G10) vs appropriate International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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controls. Briefly, tumor cells were xenografted 13 days before 
treatment (the mean ± standard deviation tumor volumes for 
the animals in this study were 558 ± 413 mm3 at the time RII 
commenced). Mice were randomly separated into 3 groups 
before treatment, and all mice received a single IV dose of 
drug via the lateral tail vein. All the SWCNT-([89Zr]DFO)(IgG) 
constructs were labeled to high SA (592 GBq/g SWCNT [16 
Ci/g]). Group 1 mice (n = 4) received a single dose of Construct 
II containing 4.18 MBq (0.113 mCi) 89Zr, 7,000 ng SWCNT, 
and 15,700 ng E4G10. Group 2 mice (n = 3) received a single 
IV 0.8 mg dose of unlabeled E4G10 (50-fold excess relative 
to the construct-associated E4G10) 30 minutes before the 
single dose of Construct II containing 4.18 MBq 89Zr, 7,000 ng 
SWCNT, and 15,700 ng E4G10. This group served as a block-
ing control. Group 3 mice (n = 3) received a single dose of the 
isotype control Construct II containing 3.08 MBq (0.083 mCi) 
89Zr, 5,200 ng SWCNT, and 12,100 ng anti-KLH.
The PET study was performed with a microPET FocusTM 
120 (CTI Molecular Imaging, Knoxville, TN, USA). Mice were 
maintained under 2% isoflurane/oxygen anesthesia during the 
scanning. Images were recorded at various time points between 
0–96 hours after injection. The list-mode data were acquired 
for between 10 and 30 minutes using a γ-ray energy window 
of 350–750 keV and a coincidence timing window of 6 ns. For 
all static images, scan time was adjusted to ensure a minimum 
of 20-million coincident events recorded. Data were sorted 
into 2-dimensional histograms by Fourier rebinning, and trans-
verse images were reconstructed by filtered back-projection 
into a 128 × 128 × 63 (0.72 × 0.72 × 1.3 mm) matrix. The 
reconstructed spatial resolution for 89Zr was 1.9 mm full width 
at half maximum at the center of the field of view. The image 
data were normalized to correct for nonuniformity of response 
of the PET, dead-time count losses, positron-branching ratio, 
and physical decay at the time of injection but no attenuation, 
scatter, or partial volume-averaging correction was applied. 
An empirically determined system calibration factor (in units 
of [mCi/mL]/[cps/voxel]) for mice was used to convert voxel 
count rates to activity concentrations. The resulting image data 
were then normalized to the administered activity to parameter-
ize images in terms of %ID/g. Manually drawn 2-dimensional 
region of interest (ROI) or 3-dimensional VOI were used to 
determined the maximum and mean % ID/g (decay corrected to 
the time of injection) in various tissues.6 Images were analyzed 
by using ASIPro VM 5.0 software (Concorde Microsystems, 
Knoxville, TN, USA).
characterization of e4g10 reactivity
LS174T, Chinese hamster ovary (CHO), and CHO cells that 
stably expressed human VE-cad were assessed for VE-cad 
expression by flow cytometry. Cells were stained with E4G10 
plus a secondary goat anti-rat phycoerythrin IgG-conjugated 
antibody (R&D Systems) and then analyzed by flow cytometry 
(FACSAria; Beckman Coulter). In addition, lysates from these 
cell lines were tested for VE-cad expression by Western blot 
analysis. The lysates were resolved on a 4%–12% NuPAGE 
Bis–Tris gel (Invitrogen) and transferred to a polyvinylidene 
difluoride membrane, and VE-cad was detected using E4G10 
plus a goat anti-rat horseradish peroxidase IgG–conjugated 
antibody (R&D Systems). In addition, glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was included as a loading 
control and was measured to evaluate protein loading using 
an anti-GAPDH pAb (R&D Systems).
Data analyses
Three-dimensional VOI analysis on PET images was 
accomplished with ASIPro VM 5.0 software (Concorde 
Microsystems). Statistical data were evaluated using 
Graphpad Prism 5.0 (Graphpad Software Inc, La Jolla, 
CA, USA). Analysis of NIR images used the VisEn FMT-
2500 instrument’s TrueQuant software (VisEn Medical). 
Statistical comparison between 2 experimental groups was 
performed using a t test (unpaired comparison); comparison 
of multiple groups was performed with the one-way analysis 
of variance using Bonferroni’s multiple comparison post hoc 
analysis. All statistical comparisons were 2-sided, and the 
level of statistical significance was set at P , 0.05.
Results
Construct syntheses and amplification  
of specific activity
The SWCNT-(DOTA)(HNH) precursor to Construct I was 
assayed and found to contain 1 mmol DOTA and 0.06 mmol 
HNH per gram of SWCNT. This precursor was radiolabeled 
(reaction 1) with 5 different amounts of 225Ac activity, which 
after SEC purification yielded 96% radiochemically pure 
SWCNT-([225Ac]DOTA)(HNH). The SA for the 5 reaction 
products was 2.15, 4.07, 12.1, 108, and 914 GBq/g (0.058, 0.11, 
0.326, 2.91, and 24.7 Ci/g, respectively). The 2 antibody compo-
nents, E4G10-FB and the isotype control anti-KLH-FB, had 5–7 
FB reactive groups appended per IgG (reaction 2). These IgG 
precursors were in turn reacted (reaction 3) in 5-fold excess (per 
100 nm of SWCNT) with the SWCNT-([225Ac]DOTA)(HNH) 
(0.058 and 24.7 Ci/g) precursors to yield the RIT Construct I at 
two different SA and the nontargeting high-SA isotype control 
Construct I. Approximately 3 IgG per construct were appended 
per SWCNT. The starting amount of radioactivity used in the 
reaction is plotted vs the resultant SA (Figure 2).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
792
Ruggiero et al
The preclinical radiolabeling data for 225Ac-E4G10 
yielded SA of 6.7 ± 4.4 GBq/g (0.18 ± 0.12 Ci/g) with RCP 
of 96.7% ± 2.6%. The radiolabeled clinical IgG,  225Ac-
lintuzumab, yielded SA of 6.7 ± 1.9 GBq/g (0.18 ± 0.05 
Ci/g) with RCP of 97.2% ± 2.5%. A comparison of the 
SWCNT-(DOTA)(HNH) precursor and the IgG construct 
labeling results demonstrates that the increased amount of 
DOTA per SWCNT yields almost a 2-log amplification of 
SA vs the IgG-DOTA constructs (Figure 2).
The N-succDFO product was obtained in 62% yield. High 
resolution mass spectrometry confirmed the product identity 
(HRMS-ES+ Calculated for [C29H52 N6O11 + H+] = 661.3772; 
found 661.3760 ([M + H+] = 100%).
The SWCNT-(DFO)(FB) precursor to Construct II was 
assayed and found to contain 0.4 mmol DFO and 0.3 mmol 
FB per gram of SWCNT. This precursor was radiolabeled 
with 89Zr activity, which after SEC purification yielded 97% 
radiochemically pure SWCNT-([89Zr]DFO)(FB) (reaction 4). 
The SA was 592 GBq/g (16 Ci/g). To assemble Construct II, ∼11 
HNH reactive groups were appended per IgG to yield E4G10-
HNH and the isotype control anti-KLH-HNH (reaction 5). 
These antibody precursors were in turn reacted with the 
SWCNT-([89Zr]DFO)(FB) precursor in 10-fold excess (to 
SWCNT) to yield the RII Construct II and the nontargeting 
isotype control Construct II (reaction 6). Approximately 3 
IgG per construct were appended per SWCNT.
PK profile of E4G10 and the number  
of Ve-cad monomer epitopes per cell
The E4G10-AF680 and anti-KLH-AF680 constructs 
prepared for the FMT tumor NIR imaging and PK studies 
were prepared in 75% and 51% yield, respectively. Spec-
trophotometric analysis revealed that there were 5.5 AF680 
appended per E4G10 and 10.2 AF680 per anti-KLH isotype 
control. Both constructs were 99% pure as determined by 
HPLC analysis. The amount of dye that accumulated in each 
tumor was imaged and measured on days 1, 2, 3, 5, 6, and 
7 by FMT imaging. NIR FMT images of 2 representative 
mice demonstrate the differential targeting of the VE-cad 
epitope in the LS174T tumor vessels with E4G10-AF680 
vs a similarly prepared isotype anti-KLH-AF680 nontar-
geting control construct 7 days after injection (Figure 3). 
There was 1.2 ± 1 pmol E4G10-AF680 (mean ± standard 
deviation) vs 0.04 ± 0.06 pmol anti-KLH-AF680 per group 
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Figure 3 Near-infrared three-dimensional fluorescent-mediated tomographic images of 2 representative mice showing the targeting of the monomeric VE-cad epitope in the 
subcutaneous Ls174T tumor with A) e4g10-AF680 vs B) anti-KLh-AF680, a similarly prepared nontargeting isotype control construct, 7 days after injection.
Abbreviations: Ve-cad, vascular endothelial-cadherin; anti-KLh, anti-keyhole limpet hemocyanin.
(n = 5 mice per group) on day 7 representing a 30-fold excess 
of signal-to-noise at this time.
A kinetic analysis of this data yielded the concentration 
of IgG-AF680 per tumor per day (Figure 4), which demon-
strated a blood compartment clearance time of ∼3 days. The 
tumor volumes (mean ± standard deviation) of the E4G10-
AF680 group were 1,208 ± 444 mm3 (n = 5), and the anti-
KLH-AF680 group had tumor volumes of 1,022 ± 667 mm3 
(n = 5) on the second day of NIR FMT imaging study. This 
PK data were also used to calculate an estimate of the num-
ber of VE-cad per VE cell. In the E4G10-AF680 group, the 
mean tumor volume was 1,208 mm3, and 3.2 ± 0.08 pmol 
of E4G10 was accumulated after the blood compartment 
clearance. Using data from Hilmas and Gillette49 along with 
the aforementioned assumptions, there were 1.44E7 VE cells 
in the tumor with 1.33E5 VE-cad epitopes per VE cell. (The 
isotype control group that received the anti-KLH-AF680 had 
0.27 ± 0.25 pmol of antibody in the tumor.)
RIT targeted to the tumor vessels 
improved median survival and tumor 
regression
A single administration of the high SA Construct I to the 
RIT group 1 mice significantly improved the median survival 
relative to the RIT group 4 mice (the growth controls; 26 days 
vs 12.5 days; P = 0.0334). RIT group 2 mice received the 
high SA isotype control Construct I and RIT group 3 mice 
received the low SA Construct I and had median survival 
times of 13 and 14 days, respectively. The Kaplan–Meier 
survival plot and the plot of the change in tumor volumes 
from time of treatment showed the benefit of a single dose, 
high SA Construct I relative to controls (Figure 5). It was 
observed that on day 10 after treatment, there was a notice-
able transient decrease in tumor volume in RIT group 1 mice 
compared with other groups. Photographic images (Figure 6) 
of a representative mouse from RIT groups 1 and 3 are shown 
at day 10 from treatment to illustrate the therapeutic effect 
of the high SA drug construct control vs the low SA drug 
construct control. The tumor volume was significantly less 
in the RIT group 1 mouse with a lesion scar in the center of 
the tumor area.
RII of tumor vasculature
A single IV administration of Construct II to the RII group 
1 mice via the lateral tail vein showed rapid accumulation 
by PET ROI analysis of signal in the tumor (∼0.36% ID/g 
at 24 hours after injection) (Figure 7A). RII group 2 mice 
(n = 3) received a single IV 0.8 mg dose of unlabeled E4G10 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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(50-fold excess relative to the construct-associated E4G10) 
30 minutes prior to a single dose of Construct II and did 
not show accumulation of signal in the tumor (∼0.24% ID/g 
at 24 hours after injection) (Figure 7B). RII group 3 mice 
(n = 3) received a single dose of the isotype control Con-
struct II and did not show accumulation of signal in the 
tumor (∼0.18% ID/g at 24 hours after injection) (Figure 7C). 
Other imaging data (Figure 8A) was taken from dynamic 
PET measurements in the first hour after administration 
which showed clearly the rapid blood compartment clearance 
(t1/2 = 15 minutes). The tumor accumulation in a representa-
tive RII group 1 mouse showed rapid and persistent accumu-
lation of drug, whereas a representative RII group 3 control 
mouse demonstrated decrease of tumor-associated activity 
in the first 5 minutes that leveled off and appeared as noise. 
Further PET ROI data (Figure 8B) from a   representative 
mouse from RII group 1 was plotted as a function of time at 
1, 4, 24, and 96 hours and showed a tumor-to-muscle ratio of 
1.61, 1.98, 2.95, and 5.08, respectively. The tumor-to-muscle 
ratios were highest at 96 hours, but reasonable contrast 
was apparent between 4 and 24 hours. This demonstrated 
a significant improvement over the E4G10-alone imaging 
agent that required ∼3–4 days for the blood compartment 
activity to clear.
Discussion
The concurrent processes of angiogenesis and tumor cell 
proliferation are keys to tumor growth and dissemination 
and are interrelated by a paracrine effect.51 Endothelial 
cells will expand to produce a tortuous network of vessels 
that supplies required nutrients, oxygen, cytokines, and 
chemokines to tumor cells. Disrupting and damaging the 
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vascular endothelial architecture associated with tumor tissue 
have been recognized as a viable therapeutic strategy.51–57 
Furthermore, imaging modalities that can specifically target 
the tumor vessels would be of value in diagnosing disease 
and following the progression or regression as a function 
of treatment.58,59
We hypothesized that novel synthetic structures based 
on hybrid molecules consisting of targeting biologics, 
radionuclides, and CNTs will have emergent anticancer 
properties. These molecular hybrids were designed to amplify 
the intrinsic targeting, binding, imaging, and therapeutic 
attributes of a drug construct and should, therefore, improve 
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potency, specificity, and efficacy relative to current drugs. 
Irradiation of the vessels associated with tumor tissue 
was effected by specifically targeting the high LET alpha 
particle-emitting 225Ac in high SA to the VE-cad epitope; 
however, imaging the tumor vessels was effected by specifi-
cally targeting the same epitope with the positron-emitting 
89Zr in high SA.
We previously demonstrated that an alpha particle- 
emitting, vascular-targeting antibody construct, 225Ac-E4G10, 
could specifically irradiate prostate carcinoma vascular 
endothelial cells27 and also their bone marrow-derived 
endothelial progenitors,28 delaying tumor growth and 
improving survival. We have also examined 225Ac-E4G10 in 
vascular-targeting strategies to treat animal models of 
glioblastoma mutiforme25,26 and the colon carcinoma 
(LS174T) model of tumor vasculature.60 Others have 
also used vascular-targeting, alpha particle-emitting RIT 
approaches to treat animal models of disease61–64 or vascu-
lar/tumor epitope-targeting RII approaches to PET image 
tumor.65–67
Two particular SWCNT properties, the high aspect 
ratio and the periodic structure, have rendered this nano-
material amenable to being simultaneously appended with 
multiple copies of reactive primary amines, radiometal-ion 
chelates (DOTA or DFO), and IgGs. By amplifying the 
number of chelates per SWCNT, we have demonstrated a 
2-log increase of SA of radiolabeling of SWCNT-(DOTA) 
relative to IgG constructs. Each of these SWCNT molecules 
had ∼100 DOTA or DFO chelates appended per SWCNT. 
In contrast, an IgG might only accommodate 5–10 DOTA 
moieties per molecule before losing the ability to target 
and bind efficiently.68
The radiotherapeutic SWCNT constructs, labeled with 
225Ac, were also functionalized with multiple copies of E4G10 
antibody and used to treat LS174T tumors vs low SA con-
trol, nontargeting high SA isotype IgG control, and growth 
control. Survival of animals treated with high SA Construct 
I was doubled after only one treatment relative to the control 
groups and was significantly better than the growth controls. 
Tumor growth was also arrested and regressed in the high 
SA RIT group 1. The mice treated with the high SA, tumor 
vascular-targeting Construct I showed significant tumor 
regression while the low SA targeting analog did not control 
tumor growth. The image of the regressed tumor lesion was 
similar to the images obtained by Nilsson and Neri69 who 
targeted the delivery of tissue factor to the ED-B domain 
of fibronectin, a marker of angiogenesis, and mediated the 
infarction of solid tumors in mice.
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Figure 7 PeT images of 3 representative subcutaneous Ls174T tumored mice that received an IV injection of A) sWcNT-([89Zr]DFO)(e4g10); B) low sA 89Zr-DFO-
sWcNT-e4g10 (competitive inhibition or blocking control experiment); and C) nonspecific control construct SWCNT-([89Zr]DFO)(anti-KLh) recorded at 24 hours after 
injection. The top panel is the transverse image and the bottom panel is the coronal image. The notations T, L, Ki, and B indicate the tumor, liver, kidneys, and bladder, 
respectively.
Abbreviations: PeT, positron emission tomography; IV, intravenous; sWcNT, single wall carbon nanotube; 89Zr, zirconium-89; DFO, desferrioxamine B; SA, specific 
activity; anti-KLh, anti-keyhole limpet hemocyanin; Trans, transverse.
Figure 6 Two representative Ls174T-xenografted mice from the radioimmuno- 
therapeutic  study  10  days  after  treatment.  A)  A  mouse  treated  with  high  sA 
sWcNT-([225Ac]DOTA)(e4g10).  B)  A  mouse  treated  with  low  sA  sWcNT-
([225Ac]DOTA)(e4g10).
Abbreviations: sA, specific activity; SWCNT, single wall carbon nanotube; 225Ac, 
actinium-225; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.
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The increased SA was also key to achieving a high 
signal-to-noise ratio for imaging purposes. We have utilized 
this increased sensitivity with indium-111 (111In) and  86Y 
labeled SWCNT-(DOTA) constructs for PK studies.3–6 In 
addition, covalently SWCNT-appended IgG and peptides 
have conferred biological targeting and binding capabili-
ties to this scaffold and bind to the specific antigen epitope 
in vitro and in vivo.3,5 We were able to improve the SA of the 
89Zr-labeled RII Construct II ∼5-fold relative to 89Zr-labeled 
IgG-only labeled constructs.30
Another key SWCNT property that was utilized 
extensively was the favorable PK profile that featured 
rapid blood compartment clearance. The RII Construct II 
targeted and bounded and then rapidly cleared the blood 
compartment and the muscle yielding excellent contrast for 
imaging. The targeting system also favored this profile as 
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Figure 8 PeT data showing tumor accumulation and corresponding blood and muscle clearance of the construct as a function of time. A) TAc from 2 representative 
Ls174T-xenografted-mice  that  were  dynamically  PeT  imaged  immediately  after  IV  administration  of  sWcNT-([89Zr]DFO)(e4g10)  and  sWcNT-([89Zr]DFO)
(e4g10) + excess unlabeled e4g10 (cold blocking control). Tumor accumulation (blue circles) and blood compartment clearance (green squares) were determined 
by ROI analysis for the mouse that received the dose of sWcNT-([89Zr]DFO)(e4g10). similarly, tumor accumulation (red triangles) and blood compartment 
clearance (yellow diamonds) were determined by ROI analysis for the mouse that received the blocking dose of excess e4g10 and then the dose of sWcNT-
([89Zr]DFO)(e4g10). B) PeT ROI data showing tumor (blue bars) and muscle (orange bars) accumulation (mean ± standard deviation) as a function of time for a 
representative Ls174T-xenografted mouse that received a dose of sWcNT-([89Zr]DFO)(e4g10). The numerical values listed above the tumor data are the tumor-
to-muscle ratios.
Abbreviations:  PeT,  positron  emission  tomography;  TAc,  time  activity  curve;  IV,  intravenous;  sWcNT,  single  wall  carbon  nanotube;  89Zr,  zirconium-89;  DFO, 
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the murine VE-cad epitope is expressed in the vessel lumen 
and, therefore, is readily accessible to the CNT construct. 
The binding occurred rapidly, precluding any need to diffuse 
into the solid tumor to target and bind. All of these studies 
demonstrated that the administered constructs were safe 
and well tolerated.
The SWCNT-E4G10 construct was tumor vessel specific 
and targeted the murine VE-cad. E4G10 did not cross-react 
with the LS174T tumor cells in flow cytometric or Western 
blot analyses (Figure 9). Furthermore, the normal, resting 
vasculature no longer exposes this epitope to the E4G10 
IgG for binding,9 thus sparing normal vessels. An illustra-
tion of this VE-cad targeting concept using IV delivered 
soluble, targeting, radiolabeled (for imaging or therapy) 
constructs in patients with tumor is presented in Figure 10. 
The construct rapidly accesses the tumor vasculature and 
then can specifically bind to the monomeric VE-cad that is 
expressed in the neovasculature but cannot bind to resting 
vasculature with tight cell–cell contacts at the adherens 
junctions.
This E4G10/VE-cad targeting system is unlike the 
arginine-glycine-aspartic acid (RGD)-based agents that 
target the αvβ3 integrin, which is often expressed by both 
the tumor and the vascular network. The RGD/αvβ3 integrin 
system lacks the vascular specificity that we designed into 
our constructs. Targeting studies of vascular endothelial 
growth factor (VEGF)-A that is expressed in the LS174T 
human xenograft model with bevacizumab were complicated 
not only by the relatively small numbers of copies of epitope 
per tumor cell (12E3) but also by the imaging artifact that 
was created by the lack of expression of human VEGF-A in 
a mouse model.66
The NIR FMT imaging data in vivo yielded an 
estimate of the number of VE-cad expressed per vascular 
endothelial cell. Using the measured values of the moles 
of E4G10 (3.2 pmol) per tumor (1,208 mm3) and published 
vessel area values per tumor volume49 and VE cell area 
(1E-3 mm2),50 there were 1.4E7 VE cells in the tumor with 
1.3E5 VE-cad epitopes per VE cell. The VE-cad epitope 
was not expressed by the LS174T tumor and is a murine 
protein in the vessels of a mouse model. Baumgartner and 
Drenckhahn70 reported 6E6 VE-cad dimers (12E6 VE-
cad monomers) for immortalized mouse microvascular 
endothelial cells (MyEND) as determined in vitro using 
affinity chromatography and trypsinization. Our value 
was 90-fold lower than their value; however, it might be 
safely assumed that most of the vascular endothelial cells 
in our tumor were not newly formed angiogenic cells, and 
thus, the epitope was hidden. Since our value was based 
on total vascular endothelial cells, then if only 10% of the 
vascular endothelial cells in the tumor were newly formed 
or had irregularly or poorly connected adherens junctions, 
A
B
C
o
u
n
t
s
C
o
u
n
t
s
C
o
u
n
t
s
Isotype + GAR-PE
CHO
PE-A PE-A PE-A
CHO VE-cad
CHO 
VE-cad
LS174T
LS174T CHO
120
100
VE-cadherin
IB:E4G10
GAPDH
0
2
0
4
0
6
0
8
0
1
0
0
0
2
0
4
0
6
0
8
0
1
0
0
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
EAG10 + GAR-PE and
Figure 9 characterization of the e4g10 antibody. A) Western blot analysis of e4g10 binding to cell lysates from the (chO), Ve-cad-transfected chO, and Ls174T cells. 
gAPDh was included as a loading control. B) Flow cytometric analysis showed the binding characteristics of e4g10 with the chO, Ve-cad-transfected chO, and Ls174T 
cells. The Igg isotype control was the anti-KLh antibody. The secondary Igg was a goat anti-rat phycoerythrin Igg.
Abbreviations: chO, chinese hamster ovary; Ve-cad, vascular endothelial-cadherin; gAPDh, glyceraldehyde 3-phosphate dehydrogenase; Igg, immunoglobulin g; anti-
KLh, anti-keyhole limpet hemocyanin.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
799
Targeting angiogenic tumor vasculature with carbon nanotubes
then our estimate of the number of epitopes per cell would 
increase 10-fold (1.3E6 VE-cad epitopes per VE cell). If 
the number of newly formed VE cells was only 1% of the 
total VE cell population in the tumor, then the value would 
increase 100-fold (1.3E7 VE-cad epitopes per VE cell). 
The latter assumption yielded a better correlation with the 
Baumgartner data.
Conclusion
SWCNT constructs were designed, constructed, and used 
to deliver therapeutic and imaging radionuclide cargoes 
specifically to the vessels of a solid tumor using a target 
on VE-cad found only on new vascular endothelium. The 
goal was to target the neovessels and irregular vessels 
in a tumor with these novel nanoconstructs and image 
Figure 10 A graphical illustration of the tumor vascular-targeting concept using the carbon nanotube constructs. The soluble, covalently functionalized, and radiolabeled 
constructs are delivered intravenously to the patient with tumor. The construct rapidly accesses the tumor vasculature and then can specifically bind to the monomeric 
Ve-cad that is expressed in the neovasculature but cannot bind to resting vasculature with tight cell–cell contacts at the adherens junctions. (Note, Figures are not drawn 
to scale.)International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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accumulation and evaluate the therapeutic anti-angiogenic 
effects. The construct design incorporated 100-fold ampli-
fied cargo delivery (relative to the gold standard for tar-
geted therapy – IgG) and was built to be multifunctional and 
thus had therapeutic or imaging cargo, as well as targeting 
capability conferred by the appended IgG. This proof of 
concept design resulted in a construct with therapeutic 
efficacy, good image contrast, and specificity for the target. 
This amplified SA may prove important in delivering potent 
enough therapy and sensitive enough diagnostic signals 
simultaneously to the tumor. Our data also provided support 
of the use of nanomaterials in vascular-targeting strategies. 
These SWCNT construct doses were well tolerated and safe 
in these animal models. The number of VE-cad epitopes per 
tumor was measured and extrapolated to estimate a num-
ber of bound VE-cad epitopes per cell. These latter results 
along with the PK profile will be of use in designing more 
optimized therapeutic and imaging studies with these con-
structs. Moving forward, it is anticipated that a single con-
struct could be designed to incorporate both the imaging and 
therapeutic cargoes onto the same platform. Furthermore, 
because the construct targets an epitope expressed by the 
tumor vascular network, a single agent could be employed 
to image or treat a variety of different tumors.
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